Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Investor Presentation (February 2025)
10 slides from Oncosil Medical's investor presentation, Feb 11, 2025
Slide 1: Webinar Presentation
For personal use only Webinar Presentation February 11, 2025 Nigel Lange, CEO & Managing Director ASX Code: OSL 1
Slide 2: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the informat
Slide 3: OncoSil continues to hit material operational targets
OncoSil continues to hit material operational targets Achievements against strategy: financial year to date Operational Financial For personal use only Expanded global presence via exclusive distribution $0.402 million revenue from commercial sales during agreements in GCC, Egypt and Nordics the
Slide 4: In detail today
In detail today Recent operational achievements and what they mean for strategy For personal use only 1. G-BA approval for testing new treatment method "Endoscopic injection-implantation of 32P-labeled microparticles in unresectable, locally advanced pancreatic tumors” enables fully funded Phase III
Slide 5: G-BA fully funded trial in Germany
G-BA fully funded trial in Germany German Institute for Hospital For personal use only Federal Joint Committee Remuneration System (InEK) authorises (G-BA) recommended a fully- 120 German hospitals to negotiate funded trial take place in funding for OncoSil Device Germany Mar Oct Feb G-BA 2022 2024
Slide 6: G-BA fully funded trial in Germany: Leading to public insurance reimbursement
G-BA fully funded trial in Germany Leading to public insurance reimbursement For personal use only Feb 2025: InEK authorized 120 German hospitals to negotiate funding for the OncoSilTM device representing a 43% increase in potential access over 2024 (84 hospitals). Authorization underscores both the
Slide 7: Medical Device Regulation (MDR) certification
Medical Device Regulation (MDR) certification Lifts post-market restrictions and paves way for accelerated market access For personal use only British Standards Institution (BSI) is the EU Notified Body Receipt of MDR removes administrative burden and requirement for ethics committee approval sa
Slide 8: Ongoing Clinical Trials
Ongoing Clinical Trials TRIPP-FFX PANCOSIL An open-label, multi-centre, randomized study of TaRgeted Safety and feasibility of CT-guided percutaneous radionuclide For personal use only Intratumoural Placement of Phosphorous-32 (OncoSil ) in therapy with the OncoSil device in patients with non- addit
Slide 9: Summary
Summary G-BA approval enables fully funded, revenue positive CED trial For personal use only Next steps: CRO tender and clinical trial protocol design (G-BA timeline) Authorisation by the German Institute for the Hospital Remuneration System underscores growing recognition of OncoSilTM device in Ger
Slide 10: Nigel Lange, CEO & Managing Director
For personal use only Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com Learn more about OncoSil Medical: • Website • ASX announcements • LinkedIn
OncoSil Medical — Investor Presentation (February 2025) on 6ix